Business Context and Reporting Period
SelectQuote, Inc. (SLQT) is a technology-enabled, direct-to-consumer distribution platform for insurance policies and healthcare services. The company operates three primary reportable segments: Senior (Medicare-related insurance), Healthcare Services (pharmacy and chronic care management), and Life (term and final expense insurance). This summary covers the quarterly period ended March 31, 2026 (Fiscal Q3 2026) and the nine months ended March 31, 2026.
Key Financial Metrics
| Metric | Q3 2026 (3 Months) | Q3 2025 (3 Months) | YTD 2026 (9 Months) | YTD 2025 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $430.9 million | $408.2 million | $1,296.8 million | $1,181.5 million |
| Net Income | $40.2 million | $26.0 million | $79.0 million | $34.7 million |
| Net Income Attributable to Common Shareholders | $21.4 million | $20.2 million | $24.6 million | $28.9 million |
| Diluted EPS (Common) | $0.11 | $0.03 | $0.11 | $0.13 |
| Operating Cash Flow (YTD) | $35.2 million | $25.8 million | $35.2 million | $25.8 million |
| Total Debt (Gross) | $375.8 million | $385.1 million | $375.8 million | $385.1 million |
| Cash & Equivalents | $36.3 million | $37.1 million | $36.3 million | $37.1 million |
Note: Net Income includes a significant non-cash gain from the change in fair value of warrants ($27.5 million for Q3; $61.8 million YTD). Adjusted EBITDA for Q3 2026 was $44.6 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 6% in Q3 and 10% YTD compared to the prior year. This was driven by a 24% YTD increase in Pharmacy revenue (Healthcare Services) and a 11% YTD increase in Life revenue.
- Profitability: Net income increased significantly due to a reduction in interest expense (down 48% Q3, 49% YTD) following debt refinancing and a large non-cash gain from warrant valuation changes. However, Net Income attributable to common shareholders decreased YTD due to preferred stock dividends and accretion.
- Debt Restructuring: In January 2026, the company entered a new Senior Secured Credit Facility ($325M Term Loan, $90M Revolver) to repay previous obligations. This resulted in an $8.7 million loss on extinguishment of debt recorded in Q3.
- Segment Performance:
- Senior: Revenue increased 8% Q3 but decreased 3% YTD, primarily due to lower carrier-sponsored production incentives.
- Healthcare Services: Revenue increased 5% Q3 and 23% YTD, driven by an 11% increase in SelectRx members.
- Life: Revenue increased 4% Q3 and 11% YTD, driven by higher policy volumes in final expense products.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The financial results were significantly impacted by a $61.8 million non-cash gain from the change in fair value of warrant liabilities (due to stock price movements) and an $8.7 million loss on debt extinguishment. Additionally, the company began receiving manufacturer refunds under the Inflation Reduction Act, which are reported as a reduction to Cost of Goods Sold rather than revenue, impacting gross margin presentation.
- Legal Proceedings: The company is involved in a qui tam action (DOJ Action) alleging violations of the Federal False Claims Act regarding sales practices. The court denied motions to dismiss on most counts. Several securities class actions and derivative suits remain pending or stayed.
- Listing Risk: On March 19, 2026, SelectQuote received notice from the NYSE that its common stock failed to meet the minimum $1.00 closing price requirement for 30 consecutive days. The company has a six-month cure period to regain compliance or face delisting.
- Outlook: Management expects existing cash, credit facility availability, and operating cash flows to be sufficient for working capital and debt service. No specific forward-looking financial guidance was provided in this filing.
Investor Verification Checklist
- Delisting Risk: Verify the current stock price and the company's plan to regain NYSE compliance within the six-month cure period.
- Warrant Liability Volatility: Assess the impact of the $61.8 million non-cash warrant gain on reported net income; this item is highly volatile and does not reflect operating cash generation.
- Preferred Stock Obligations: Review the terms of the $350 million Senior Non-Convertible Preferred Stock, including the 14.5% dividend rate and accretion, which significantly reduces earnings available to common shareholders.
- Legal Exposure: Monitor the status of the DOJ qui tam action and related securities litigation, as unfavorable outcomes could result in significant penalties or damages.
- Pharmacy Margins: Analyze the impact of the Inflation Reduction Act manufacturer refunds on the reported Cost of Goods Sold and future pharmacy margin trends.